ATRenew (NYSE:RERE – Get Free Report) is scheduled to release its earnings data before the market opens on Wednesday, November 20th. Analysts expect ATRenew to post earnings of $0.05 per share for the quarter. ATRenew has set its Q3 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.
ATRenew (NYSE:RERE – Get Free Report) last announced its earnings results on Tuesday, August 20th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.01). The business had revenue of $519.69 million for the quarter, compared to the consensus estimate of $514.00 million. ATRenew had a negative net margin of 0.99% and a positive return on equity of 4.80%. On average, analysts expect ATRenew to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ATRenew Trading Up 0.4 %
Shares of ATRenew stock opened at $2.39 on Monday. ATRenew has a 1 year low of $1.01 and a 1 year high of $3.18. The company’s fifty day simple moving average is $2.52 and its 200-day simple moving average is $2.47. The company has a market cap of $582.85 million, a price-to-earnings ratio of -26.55, a PEG ratio of 0.55 and a beta of -0.13.
ATRenew Company Profile
ATRenew Inc, through its subsidiaries, operates pre-owned consumer electronics transactions and services platform in the People's Republic of China. It primarily sells mobile phones, laptops, tablets, drones, digital cameras; and vintage bags, watches, liquor, gold, and various household goods through its online platforms and offline stores, as well as provides services to third-party merchants to sell the products through its platforms.
Featured Stories
- Five stocks we like better than ATRenew
- How to Invest in Insurance Companies: A GuideĀ
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What to Know About Investing in Penny Stocks
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Using the MarketBeat Dividend Tax Calculator
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for ATRenew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRenew and related companies with MarketBeat.com's FREE daily email newsletter.